-

Agilent’s Certified Pre-Owned Instruments Program Receives Environmental Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company’s Certified Pre-Owned Instruments Program received a Top Project award for achieving outstanding results in reducing waste. The award is sponsored by Environment+Energy Leader, a leading publisher of environmental, energy and sustainability best practices and research.

Agilent’s Certified Pre-Owned Instruments Program gives Agilent lab customers the option to trade in their used analytical instrument for cash or toward the purchase of a new instrument. Customers can also return select decommissioned instruments to Agilent for recycling.

Agilent refurbishes used systems to new instrument standards, then resells them to customers who might not otherwise have access to high-quality instruments due to budget constraints. Systems that cannot be refurbished to Agilent’s high standards are evaluated for part reuse and recycling wherever feasible.

In fiscal year 2021, Agilent bought back over 900 used instruments from customers; sold over 3,500 certified pre-owned instruments; and took back 2,000 instruments through the program.

The Certified Pre-Owned Instruments Program is a contributor to Agilent’s Environmental, Social and Governance (ESG) focus and complements other product sustainability initiatives within the company, including designing analytical instruments to use less energy and produce less waste; product labeling that indicates the environmental footprint of select Agilent instruments; leadership in lab sustainability practices; and digital technology like CrossLab Connect that enable labs to operate more efficiently through automation, artificial intelligence, and virtual support. The initiative also advances Agilent’s commitment to achieving net-zero emissions by 2050.

Learn more about the award and Agilent’s Certified Pre-Owned Instruments and trade-in and recycling services.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter and Facebook.

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions
$Cashtags

Contacts

Sarah Litton
+1 669 255 7696
sarah.litton@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom